DMG PEG2000 Azide Conjugate

Description

DMG PEG2000 Azide Conjugate Catalog B2013531 (25 mg)

DMG PEG2000 Azide Conjugate is a specialized lipid-PEG compound featuring a dimyristoyl glycerol lipid anchor tethered to a 2,000 Da PEG chain capped with an azide functional groupoptimized for click-chemistry applications and nanocarrier surface engineering. Supplied as a refined powder (Catalog B2013531, 25 mg), this conjugate is designed for seamless incorporation into lipid bilayers of liposomes, micelles, and nanoformulations. The azide moiety enables strain-promoted click reactions under mild physiological conditions, facilitating precise conjugation with alkynyl or DBCO-functionalized biomolecules without compromising structural integrity.

Manufactured to high biotech-grade standards, DMG PEG2000 Azide ensures reproducibility and batch consistency, making it an excellent choice for constructing targeted delivery systems, functionalized imaging probes, or modular biosensors. The stabilizing PEG segment enhances solubility and reduces aggregation, while the DMG anchor secures membrane association. Powder format and 20 C storage support long-term usability, and bulk supply is available for scale-up applications.

Why researchers choose this product:

• Combines lipid anchoring, PEG stabilization, and click-ready azide chemistry in one molecule
• Supports modular assembly of nanocarriers, probes, and conjugates via bio-orthogonal reactions
• High purity ensures minimal background and reliable reaction outcomes
• Powder form enables accurate handling and long-term stability
• Bulk quantities available for high-throughput or large-scale workflows

Indication for Use:
This product is for Research Use Only (RUO). It is not intended for human or animal therapeutic or diagnostic use.

References

• Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines Mol Ther. 2021 Mar 3;29(3):898-900.
• Zimmermann CM, Baldassi D, Chan K, Adams NBP, Neumann A, Porras-Gonzalez DL, Wei X, Kneidinger N, Stoleriu MG, Burgstaller G, Witzigmann D, Luciani P, Merkel OM. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery J Control Release. 2022 Nov;351:137-150.
• Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis J Clin Pharmacol. 2020 Jan;60(1):37-49.
• Vespa S, Del Biondo P, Simeone P, Cavallucci E, Catitti G, Auciello R, De Bellis D, Altomare I, Pierdomenico L, Canonico B, Cicalini I, Angilletta I, Del Boccio P, Pieragostino D, Santilli F, Urbani A, De Laurenzi V, Stuppia L, Lanuti P. Basophil Activation Test with Different Polyethylene Glycols in Patients with Suspected PEG Hypersensitivity Reactions Int J Mol Sci. 2022 Nov 23;23(23):14592.
• Waggoner LE, Miyasaki KF, Kwon EJ. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury Biomater Sci. 2023 Mar 29.
• Khare P, Conway JF, S Manickam D. Lipidoid nanoparticles increase ATP uptake into hypoxic brain endothelial cells Eur J Pharm Biopharm. 2022 Nov;180:238-250.
• Chen J, Rizvi A, Patterson JP, Hawker CJ. Discrete Libraries of Amphiphilic Poly(ethylene glycol) Graft Copolymers: Synthesis, Assembly, and Bioactivity J Am Chem Soc. 2022 Oct 26;144(42):19466-19474.
• Zhao W, Zhang C, Li B, Zhang X, Luo X, Zeng C, Li W, Gao M, Dong Y. Lipid Polymer Hybrid Nanomaterials for mRNA Delivery Cell Mol Bioeng. 2018 Oct;11(5):397-406.
• Khokhar D, OShea KM, Akin C, Baldwin JL, Benjamin MR, Ravikumar R, Hosler M, McMorris MS, Sanders GM, Troost JP, Baptist AP, Oberdoerster DT, Kovalszki A. Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopy J Allergy Clin Immunol Glob. 2022 Nov;1(4):209-216.